These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18825277)

  • 41. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
    Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
    Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
    Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
    Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
    Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
    Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
    Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
    De Grève J; Moran T; Graas MP; Galdermans D; Vuylsteke P; Canon JL; Schallier D; Decoster L; Teugels E; Massey D; Chand VK; Vansteenkiste J
    Lung Cancer; 2015 Apr; 88(1):63-9. PubMed ID: 25682316
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
    Weinberger PM; Yu Z; Kowalski D; Joe J; Manger P; Psyrri A; Sasaki CT
    Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):707-11. PubMed ID: 16103303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Significance of expression of epidermal growth factor (EGF) and its receptor (EGFR) in chronic cholecystitis and gallbladder carcinoma].
    Zhou YM; Li YM; Cao N; Feng Y; Zeng F
    Ai Zheng; 2003 Mar; 22(3):262-5. PubMed ID: 12654182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF
    Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of P53, E-cadherin, Cox-2, and EGFR protein immunoexpression on prognostic of resected gallbladder carcinoma.
    Pais-Costa SR; Farah JF; Artigiani-Neto R; Martins SJ; Goldenberg A
    Arq Bras Cir Dig; 2014; 27(2):126-32. PubMed ID: 25004291
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
    Thomas DG; Giordano TJ; Sanders D; Biermann S; Sondak VK; Trent JC; Yu D; Pollock RE; Baker L
    Cancer; 2005 Feb; 103(4):830-8. PubMed ID: 15641030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of EGFR and HER-2/NEU Expression in Gall Bladder Carcinoma (GBC).
    Das C; Mukhopadhyay M; Subba S; Saha AK; Mukhopadhyay B
    J Lab Physicians; 2021 Mar; 13(1):29-35. PubMed ID: 34103877
    [No Abstract]   [Full Text] [Related]  

  • 52. EGFR and HER2 expression in advanced biliary tract cancer.
    Harder J; Waiz O; Otto F; Geissler M; Olschewski M; Weinhold B; Blum HE; Schmitt-Graeff A; Opitz OG
    World J Gastroenterol; 2009 Sep; 15(36):4511-7. PubMed ID: 19777609
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical significance of syndecan-1 and syndecan-2 expression in gallbladder squamous cell/adenosquamous carcinoma and adenocarcinoma].
    Tan XG; Yang ZL; Miao XY; Liu ZR; Li DQ; Zou Q; Li JH; Liang LF
    Zhonghua Zhong Liu Za Zhi; 2018 Jan; 40(1):28-34. PubMed ID: 29365414
    [No Abstract]   [Full Text] [Related]  

  • 54. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.
    Hudelist G; Singer CF; Manavi M; Pischinger K; Kubista E; Czerwenka K
    Breast Cancer Res Treat; 2003 Aug; 80(3):353-61. PubMed ID: 14503808
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
    Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
    Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterisation of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma.
    Yeh TS; Jan YY; Chiu CT; Ho YB; Chen TC; Lee KF; Chan KM; Hsu JC; Hwang TL; Chen MF
    Gut; 2002 Nov; 51(5):712-6. PubMed ID: 12377812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.